When it comes to oncology care, payors face two challenges: managing risk and ensuring better outcomes across the cancer care continuum. We show you how meeting one goal helps achieve the other — and that you don’t have to take on either alone.Find out how
From launch strategies to adherence programs to outcome reporting, we work with you to reach your goals for your drugs. Our custom solutions enhance patient access, and our care management models encourage patients to stay on therapy. It’s all part of our integrative cancer care approach.Find out how
Cancer therapeutics are as complex as the diseases they treat, but we can make clinical studies simpler. When you trust us to manage the details, from patient kit logistics and distribution to outcome reporting, you can concentrate on the science. We take care of everything else.Find out how
We specialize in cancer care alignment, synchronizing services so you and your patients can concentrate on treatment instead of logistics. We’re working on your patient’s behalf at every point in the cancer care continuum — so you know nothing will slip through the cracks.Find out how
KISQALI (ribociclib) Approved for the Treatment of HR+/HER2- Advanced Breast Cancer, available for order at Biologics, Inc.
CARY, N.C. (March 17, 2017) —Biologics, Inc. a McKesson Specialty Health oncology pharmacy services company, has been selected by Novartis to be a specialty pharmacy provider for KISQALI® (ribociclib). Approved by the U.S. Food and Drug Administration (FDA) on March 13, 2017, KISQALI is a kinase inhibitor indicated in combination with an aromatase inhibitor as …Read more